Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

= .001). Patients who were MRD negative had a higher probability of prolonged progression-free survival than patients with detectable residual disease, regardless of treatment group (RVD vs transplant), cytogenetic risk profile, or International Staging System disease stage at diagnosis. These resul... View More